US0028241000 - Common Stock
They don't offer the highest yields, but these strongly profitable businesses are poised to raise their payouts at a blistering pace.
The US FDA will reorganize its food safety division to consolidate several functions in the aftermath of 2022's baby formula shortage to prevent a similar occurrence.
This eclectic mix of stocks will help diversify your portfolio.
GE Healthcare released a solid report and gave steady guidance that includes ample room in the cash flow for a dividend, should the board choose to pay one.
After adding $208B in sales over two decades, AbbVie's (ABBV) monopoly over world's best selling drug Humira (adalimumab) is about to end as copycats enter. Read the full story here.
At least four Wall Street banks recently raised their price targets for the healthcare giant.
Stocks reacted well to uneven earnings and economic reports.
O Software Ultreon™ 1.0, primeira tecnologia de imagem do gênero, mescla a tomografia de coerência óptica com o poder da automação usando inteligência...
The FDA has expanded the use of Abbott Laboratories' (ABT) Proclaim XR spinal cord stimulation system to include diabetic peripheral neuropathy.
There's more to the story than the negative trends for Abbott's top and bottom lines.
Johnson & Johnson and Abbott Laboratories are 2 dividend kings guiding for growth in 2023 and are on track to increase their yield yet again.
Double beats for its latest quarter couldn't keep the bears away from the company's shares on Hump Day.
ABT earnings call for the period ending December 31, 2022.
With discretionary spending under pressure, investors are shying away from this Canadian cannabis stock today.
Overall sales topped forecasts, but organic growth missed expectations.
Despite a consensus beating Q4 2022, Abbott Laboratories (ABT) lost ~2% pre-market Wednesday as its revenue fell ~12% YoY amid disruption to baby formula production and waning COVID impact.
/PRNewswire/ -- Abbott (NYSE: ABT) today announced financial results for the fourth quarter ended Dec. 31, 2022. Fourth-quarter sales of $10.1 billion, which...
Abbott Laboratories (ABT) is scheduled to announce Q4 earnings results on Wednesday, January 25th, before market open.The consensus EPS Estimate is $0.93 (-29.5% Y/Y) and the...